non-hereditary heterotopic ossification | News Search

跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

找到 55,511 条关于 “non-hereditary heterotopic ossification”

āshibio Licenses Vantictumab for Rare Bone Disease ADO2 in Strategic Pipeline Expansion

āshibio Doses First Patient in Phase 2/3 Trial of Andecaliximab for Fibrodysplasia Ossificans Progressiva

FDA Grants Priority Review to Garetosmab for Ultra-Rare Bone Disease Fibrodysplasia Ossificans Progressiva

Ipsen's Phase II FALKON Trial for Ultra-Rare Bone Disease FOP Fails to Meet Primary Endpoint

Ipsen's Sohonos Becomes First Approved Treatment for FOP in Canada

Regeneron's Garetosmab Achieves 90% Reduction in Bone Formation in Rare Disease Trial

Regeneron Unveils Pivotal Phase 3 Garetosmab Data in FOP as FDA Priority Review Underway, Alongside Metabolic and Ophthalmology Pipeline Advances

Phase 3 Trial of NTLA-2002 for Hereditary Angioedema Now Recruiting

Ambry Genetics' CARE Program Achieves 99.5% Accuracy in Hereditary Cancer Risk Assessment

FDA Accepts Donidalorsen NDA for Hereditary Angioedema Prophylaxis

第 1 页，共 1209 页